Replies to post #140124 on Biotech Values

[biomaven0]

$150M+ peak sales wouldn't surprise me.

I think they could actually do quite a bit better than that if they get a good label and they have the ability to market the quick onset of action.

This is actually the first drug in this class that seems to have a clean enough profile so that I could maybe see some country (not the US) eventually allowing OTC use.

Peter